Weber J - Search Results

1

Ipilimumab: controversies in its development, utility and autoimmune adverse events.

Weber J. Weber J. Cancer Immunol Immunother. 2009 May;58(5):823-30. doi: 10.1007/s00262-008-0653-8. Epub 2009 Feb 6. Cancer Immunol Immunother. 2009. PMID: 19198837 Review.

2

A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu.

Pullarkat V, Deo Y, Link J, Spears L, Marty V, Curnow R, Groshen S, Gee C, Weber JS. Pullarkat V, et al. Among authors: weber js. Cancer Immunol Immunother. 1999 Apr;48(1):9-21. doi: 10.1007/s002620050543. Cancer Immunol Immunother. 1999. PMID: 10235484 Clinical Trial.

3

A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma.

Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. Weber JS, et al. J Immunother. 1999 Sep;22(5):431-40. doi: 10.1097/00002371-199909000-00007. J Immunother. 1999. PMID: 10546159 Clinical Trial.

4

Peptide vaccines for cancer.

Weber J. Weber J. Cancer Invest. 2002;20(2):208-21. doi: 10.1081/cnv-120001149. Cancer Invest. 2002. PMID: 11901542 Review.

5

Current developments of immunotherapy in the clinic.

Antonia S, Mulé JJ, Weber JS. Antonia S, et al. Among authors: weber js. Curr Opin Immunol. 2004 Apr;16(2):130-6. doi: 10.1016/j.coi.2004.01.012. Curr Opin Immunol. 2004. PMID: 15023403 Review.

6

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH. Margolin K, et al. Among authors: weber j. Cancer. 2005 Sep 1;104(5):1045-8. doi: 10.1002/cncr.21265. Cancer. 2005. PMID: 16007689 Clinical Trial.

7

The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies.

Weber JS. Weber JS. Melanoma Res. 2006 Oct;16(5):379-83. doi: 10.1097/01.cmr.0000232292.06785.a3. Melanoma Res. 2006. PMID: 17013086 Review.

8

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.

Weber J. Weber J. Oncologist. 2007 Jul;12(7):864-72. doi: 10.1634/theoncologist.12-7-864. Oncologist. 2007. PMID: 17673617 Review.

9

Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.

Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, Miles S, Liu X, Obrocea M, Qiu Z, Bot A. Weber J, et al. J Immunother. 2008 Feb-Mar;31(2):215-23. doi: 10.1097/CJI.0b013e3181611420. J Immunother. 2008. PMID: 18481391 Clinical Trial.

10

Tumor evasion may occur via expression of regulatory molecules: a case for CTLA-4 in melanoma.

Weber JS. Weber JS. J Invest Dermatol. 2008 Dec;128(12):2750-2. doi: 10.1038/jid.2008.341. J Invest Dermatol. 2008. PMID: 18997841

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results